Want to join the conversation?
Marc Goodman of UBS questions about managed care coverage for the key products for 2017, specifically Humira. CEO Rick Gonzalez said $ABBV is in active negotiations on a number of those contracts and Humira has had a strong position on managed care. He also stated that it would be premature to talk about a lot of specifics around the contracting.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?